



IMMEDIATE RELEASE

Contact:

Mark Westgate, CFO
NexMed, Inc.
89 Turn Rivers Drive
E. Windsor, NJ 08520
Phone: (609) 371-8123
Email: mwestgate@nexmed.com

Contact:

Steve King, Senior Vice President
Pharmaceutics International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
Phone: (410) 584-0001
Email: sjking@pharm-int.com

PII AND NEXMED ENTER INTO STRATEGIC COLLABORATION AGREEMENT FOR NEXMED'S NEXACT® DRUG DELIVERY PLATFORM

January 22, 2009 - PII, (Pharmaceutics International, Inc.) and NexMed, Inc. (Nasdaq: NEXM) announced today that they have signed a Memorandum of Understanding (MOU) for a strategic product development collaboration utilizing NexMed's NexACT drug delivery platform.

Pursuant to the MOU,, PII will promote the NexACT technology to its clients and may independently identify new product development opportunities for this collaboration with NexMed. PII will be responsible for the research and development of the new pharmaceutical products with technical guidance and oversight from NexMed, and will also assume responsibility for clinical trial material manufacturing and commercial manufacturing of the new products.

Hem Pandya, NexMed's COO said, "We are very pleased to enter into this collaboration with PII. The strategic goal of this agreement is to broaden the promotion of the NexACT technology platform and permit us access to PII's research and development and commercial manufacturing infrastructure. We will also be able to continue with our current product development efforts at significantly reduced monthly overhead expenses."

Steve King, PII's Senior Vice President said, "The collaboration between the companies will offer PII's customers opportunities for product development without having to move their compounds elsewhere. This technology fits well with PII's Drug Delivery Solutions initiative."



About NexMed, Inc.

NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NexMed's novel, onychomycosis treatment, licensed to Novartis, is currently in pivotal Phase 3 trials in the U.S. and Europe. In September 2007, NexMed filed a New Drug Application with the FDA for its alprostadil treatment for erectile dysfunction. NexMed's pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

About Pharmaceutics International, Inc.

A privately-held company, Pharmaceutics International, Inc. is a leading multinational contract formulation development, Clinical Trial Materials (CTM), and commercial manufacturing company with corporate headquarters in Hunt Valley, Maryland, USA. Founded in 1994 PII can manufacture a wide range of dosage forms covering solid, semi-solid and aseptic filling. This service is complemented by full analytical and regulatory support. For further information about PII go to: www.PIIdds.com / www.pharm-int.com

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.

####